Psychedelic Bulletin 212: Delix reports early efficacy signal, NRx urges FDA ban on ketamine competitors, Cybin raises $175M

Ketamine and related psychedelic-industry moves dominate Psychedelic Bulletin 212. Delix is highlighted for posting an early efficacy signal, positioning its clinical progress as a potential early win in the pipeline. The bulletin also covers NRx pushing regulators, specifically urging the FDA to ban competitors, framing the argument around market competition in ketamine-linked treatments. Cybin is another key item, raising $175M, which is presented as fresh capital to support development and commercialization efforts. Overall, the bulletin connects early clinical signals, regulatory pressure, and financing activity as the main drivers shaping near-term momentum in psychedelic therapeutics.